TrialJournal of psychopharmacology (Oxford, England)2018

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Lawrence P Carter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.